Zusammenfassung
Die Neuromyelitis optica (NMO, Morbus Devic) ist eine seltene entzündlich-demyelinisierende Erkrankung des Zentralnervensystems, die monophasisch oder relapsierend verlaufen kann. Indexereignisse sind Optikusneuritis (uni- oder bilateral) und Myelitis (≥3 Segmente). Eine zerebrale Mitbeteiligung kann vorhanden sein, bleibt aber meist asymptomatisch. Histopathologische Befunde weisen darauf hin, dass die NMO nicht als Variante der Multiplen Sklerose, sondern als eigenständige Entität anzusehen ist. Der kürzliche Nachweis eines hochspezifischen Autoantikörpers gegen Aquaporin-4, einen Wasserkanal, vereinfacht die Diagnosestellung erheblich und charakterisiert die NMO als erste Erkrankung aus dem Formenkreis der entzündlichen Demyelinisierungskrankheiten, für die ein definiertes Autoantigen identifiziert werden konnte. Neuere Therapieansätze wie Plasmaaustausch oder medikamentöse B-Zell-Depletion orientieren sich an der mutmaßlichen humoralen Autoimmunpathogenese der NMO und lassen zukünftig eine bessere Beeinflussbarkeit des vielfach ungünstigen Krankheitsverlaufs erwarten.
Summary
Neuromyelitis optica (NMO, Devic syndrome) is a rare demyelinating disease of the central nervous system which mostly follows a relapsing course. Key features of this disorder include unilateral or bilateral optic neuritis and longitudinally extensive myelitis (≥ three segments). Brain lesions are rarely present at onset. They may however evolve during the course of disease but usually remain asymptomatic. The histopathology of NMO is suggestive of an underlying humoral autoimmune pathomechanism and indicates that NMO is a distinct entity rather than a variant of multiple sclerosis. The recent detection of NMO-specific serum autoantibodies against the water channel aquaporin-4 (Aqp4) is of significant diagnostic relevance and classifies NMO as the first inflammatory demyelinating disorder of the CNS with a defined autoantigen. More recent therapeutic strategies such as plasma exchange or pharmacological B-cell depletion are expected to improve long-term prognosis of NMO.
Literatur
Aguilera AJ, Carlow TJ, Smith KJ et al. (1985) Lymphocytaplasmapheresis in Devic’s syndrome. Transfusion 25: 54–56
Amiry-Moghaddam M, Ottersen OP (2003) The molecular basis of water transport in the brain. Nat Rev Neurosci 4: 991–1001
Amiry-Moghaddam M, Williamson A, Palomba M et al. (2003) Delayed K+ clearance associated with aquaporin-4 mislocalization: phenotypic defects in brains of alpha-syntrophin-null mice. Proc Natl Acad Sci U S A 100: 13615–13620
Amiry-Moghaddam M, Frydenlund DS, Ottersen OP (2004) Anchoring of aquaporin-4 in brain: molecular mechanisms and implications for the physiology and pathophysiology of water transport. Neuroscience 129: 999–1010
Auguste KI, Jin S, Uchida K et al. (2007) Greatly impaired migration of implanted aquaporin-4-deficient astroglial cells in mouse brain toward a site of injury. FASEB J 21: 108–116
Bakker J, Metz L (2004) Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31: 265–267
Benedetti B, Valsasina P, Judica E et al. (2006) Grading cervical cord damage in neuromyelitis optica and MS by diffusion tensor MRI. Neurology 67: 161–163
Bergamaschi R (2003) Glatiramer acetate treatment in Devic’s neuromyelitis optica. Brain 126: 1E; author reply 1E-a
Bergamaschi R, Uggetti C, Tonietti S et al. (2003) A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 250: 359–361
Bergamaschi R, Tonietti S, Franciotta D et al. (2004) Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 10: 2–4
Cabrera-Gomez JA, Quevedo-Sotolongo L, Gonzalez-Quevedo A et al. (2007) Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler 13: 186–192
Cloys DE, Netsky MG (1970) Neuromyelitis optica. In: Vinken PJ, Bruyn GW (eds) Handbook of Clinical Neurology. North Holland Publishing Company, Amsterdam, pp 426–436
Compston A (2004) ‚The marvellous harmony of the nervous parts’: the origins of multiple sclerosis. Clin Med 4: 346–354
Correale J, Fiol M (2004) Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 63: 2363–2370
Cree BA, Lamb S, Morgan K et al. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270–1272
Seze J de, Stojkovic T, Ferriby D et al. (2002) Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 197: 57–61
Devic E (1894) Myélite subaiguë compliquée de névrite optique. Bull Méd 8: 1033–1034
Devic E (1895) Myelite aigue dorse-lombaire de neurite optique, autopsie. Congress Francais Medicine, Lyon, pp 434–439
Duda PW, Schmied MC, Cook SL et al. (2000) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105: 967–976
Falcini F, Trapani S, Ricci L et al. (2006) Sustained improvement of a girl affected with Devic’s disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford) 45: 913–915
Fidler JM, DeJoy SQ, Gibbons JJ Jr. (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 137: 727–732
Fidler JM, DeJoy SQ, Smith FR 3rd et al. (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 136: 2747–2754
Filippi M, Rocca MA (2004) MR imaging of Devic’s neuromyelitis optica. Neurol Sci (Suppl 4) 25: S371–S373
Fukazawa T, Kikuchi S, Miyagishi R et al. (2006) HLA-dPB1*0501 is not uniquely associated with opticospinal multiple sclerosis in Japanese patients. Important role of DPB1*0301. Mult Scler 12: 19–23
Furman CS, Gorelick-Feldman DA, Davidson KG et al. (2003) Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc Natl Acad Sci U S A 100: 13609–13614
Gartzen K, Limmroth V, Putzki N (2007) Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol 14: e12–e13
Ghezzi A, Bergamaschi R, Martinelli V et al. (2004) Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol 251: 47–52
Goehler LE, Erisir A, Gaykema RP (2006) Neural-immune interface in the rat area postrema. Neuroscience 140: 1415–1434
Green AJ, Hauser S, Cree B (2007) Funduscopic and optical coherence tomography findings in meuromyelitis optica compared to multiple sclerosis. Neurology 68: A355
Hengstman GJ, Wesseling P, Frenken CW et al. (2007) Neuromyelitis optica with clinical and histopathological involvement of the brain. Mult Scler 13: 679–682
Hiroaki Y, Tani K, Kamegawa A et al. (2006) Implications of the aquaporin-4 structure on array formation and cell adhesion. J Mol Biol 355: 628–639
Ishizu T, Osoegawa M, Mei FJ et al. (2005) Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128: 988–1002
Ito H, Yamasaki K, Kawano Y et al. (1998) HLA-DP-associated susceptibility to the optico-spinal form of multiple sclerosis in the Japanese. Tissue Antigens 52: 179–182
Jacobi C, Stingele K, Kretz R et al. (2006) Neuromyelitis optica (Devic’s syndrome) as first manifestation of systemic lupus erythematosus. Lupus 15: 107–109
Jarius S, Franciotta D, Bergamaschi R et al. (2007) NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68: 1076–1077
Jung JS, Bhat RV, Preston GM et al. (1994) Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci U S A 91: 13052–13056
Keegan M, Pineda AA, McClelland RL et al. (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58: 143–146
Kira J, Kanai T, Nishimura Y et al. (1996) Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 40: 569–574
Kobayashi H, Minami S, Itoh S et al. (2001) Aquaporin subtypes in rat cerebral microvessels. Neurosci Lett 297: 163–166
Lalive PH, Menge T, Barman I et al. (2006) Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology 67: 176–177
Lee KH, Hashimoto SA, Hooge JP et al. (1991) Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 41: 657–660
Lennon VA, Wingerchuk DM, Kryzer TJ et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106–2112
Lennon VA, Kryzer TJ, Pittock SJ et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473–477
Lin F, Yu C, Jiang T et al. (2006) Discriminative analysis of relapsing neuromyelitis optica and relapsing-remitting multiple sclerosis based on two-dimensional histogram from diffusion tensor imaging. Neuroimage 31: 543–549
Lu M, Lee MD, Smith BL et al. (1996) The human AQP4 gene: definition of the locus encoding two water channel polypeptides in brain. Proc Natl Acad Sci U S A 93: 10908–10912
Lucchinetti CF, Mandler RN, McGavern D et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125: 1450–1461
Lucchinetti CF, Bruck W, Lassmann H (2004) Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 56: 308
Lycklama G, Thompson A, Filippi M et al. (2000) Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2: 555–562
Mandler RN, Davis LE, Jeffery DR et al. (1993) Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 34: 162–168
Mandler RN, Ahmed W, Dencoff JE (1998) Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51: 1219–1220
Mandler RN, Dencoff JD, Midani F et al. (2001) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic’s neuromyelitis optica. Brain 124: 493–498
Manley GT, Fujimura M, Ma T et al. (2000) Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 6: 159–163
Matsuoka T, Matsushita T, Kawano Y et al. (2007) Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130: 1206–1223
Melamud L, Madalena L, Facio ML et al. (2006) Cerebrospinal fluid findings in Devic’s neuromyelitis optica. Mult Scler 12: P246
Misu T, Fujihara K, Kakita A et al. (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224–1234
Nakashima I, Fujihara K, Miyazawa I et al. (2006) Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 77: 1073–1075
Narikawa K, Misu T, Fujihara K et al. (2004) CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 149: 182–186
Neely JD, Amiry-Moghaddam M, Ottersen OP et al. (2001) Syntrophin-dependent expression and localization of Aquaporin-4 water channel protein. Proc Natl Acad Sci U S A 98: 14108–14113
Nielsen S, Nagelhus EA, Amiry-Moghaddam M et al. (1997) Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 17: 171–180
Nozaki I, Hamaguchi T, Komai K et al. (2006) Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry 77: 1094–1095
O’Riordan JI, Gallagher HL, Thompson AJ et al. (1996) Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 60: 382–387
Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M et al. (2002) Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry 73: 429–435
Papeix C, Vidal JS, Seze J de et al. (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13: 256–259
Paul F, Jarius S, Aktas O et al. (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4: e133
Petravic D, Habek M, Supe S et al. (2006) Recurrent optic neuromyelitis with endocrinopathies: a new syndrome or just a coincidence? Mult Scler 12: 670–673
Pittock SJ, Lennon VA, Krecke K et al. (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63: 390–396
Pittock SJ, Lucchinetti CF (2006) Inflammatory transverse myelitis: evolving concepts. Curr Opin Neurol 19: 362–368
Pittock SJ, Weinshenker BG, Lucchinetti CF et al. (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63: 964–968
Poppe AY, Lapierre Y, Melancon D et al. (2005) Neuromyelitis optica with hypothalamic involvement. Mult Scler 11: 617–621
Prineas JW, McDonald WI (1997) Demyelinating diseases. In: Graham DI, Lantos PL (eds) Greenfield’s Neuropathology. 6th edn. Arnold, London, pp 813–896
Roemer SF, Parisi JE, Lennon VA et al. (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130: 1194–1205
Saida T, Tashiro K, Itoyama Y et al. (2005) Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 64: 621–630
Satoh J, Yukitake M, Kurohara K et al. (2003) Detection of the 14–3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis. J Neurol Sci 212: 11–20
Schulz M, Engelhardt B (2005) The circumventricular organs participate in the immunopathogenesis of experimental autoimmune encephalomyelitis. Cerebrospinal Fluid Res 2: 8
Simard M, Nedergaard M (2004) The neurobiology of glia in the context of water and ion homeostasis. Neuroscience 129: 877–896
Sinclair C, Kirk J, Herron B et al. (2007) Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol (Berl) 113: 187–194
Sui H, Han BG, Lee JK et al. (2001) Structural basis of water-specific transport through the AQP1 water channel. Nature 414: 872–878
Takahashi T, Fujihara K, Nakashima I et al. (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130: 1235–1243
Tartaglino LM, Friedman DP, Flanders AE et al. (1995) Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 195: 725–732
Transverse_Myelitis_Consortium_Group (2002) Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 59: 499–505
Vernant JC, Cabre P, Smadja D et al. (1997) Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology 48: 58–64
Warabi Y, Matsumoto Y, Hayashi H (2007) Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 252: 57–61
Watanabe S, Misu T, Miyazawa I et al. (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler
Weinshenker B, Pittock SJ, Seze J de (2006) The relationship between neuromyelitis optica and systemic auto-immune disease. Mult Scler 12: O79
Weinshenker BG, O’Brien PC, Petterson TM et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46: 878–886
Weinshenker BG, Wingerchuk DM, Nakashima I et al. (2006) OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 5: 110–111
Weinshenker BG, Wingerchuk DM, Vukusic S et al. (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59: 566–569
Weinstock-Guttman B, Ramanathan M, Lincoff N et al. (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63: 957–963
Wen H, Nagelhus EA, Amiry-Moghaddam M et al. (1999) Ontogeny of water transport in rat brain: postnatal expression of the aquaporin-4 water channel. Eur J Neurosci 11: 935–945
Wingerchuk DM, Hogancamp WF, O’Brien PC et al. (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53: 1107–1114
Wingerchuk DM, Lennon VA, Pittock SJ et al. (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485–1489
Wingerchuk DM, Pittock SJ, Lucchinetti CF et al. (2007) A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68: 603–605
Yang B, Ma T, Verkman AS (1995) cDNA cloning, gene organization, and chromosomal localization of a human mercurial insensitive water channel. Evidence for distinct transcriptional units. J Biol Chem 270: 22907–22913
Yong VW (2002) Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 59: 802–808
Yu CS, Lin FC, Li KC et al. (2006) Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am J Neuroradiol 27: 1009–1015
Yu CS, Zhu CZ, Li KC et al. (2007) Relapsing neuromyelitis optica and relapsing-remitting multiple sclerosis: differentiation at diffusion-tensor MR imaging of corpus callosum. Radiology 244: 249–256
Zaffaroni M (2004) Cerebrospinal fluid findings in Devic’s neuromyelitis optica. Neurol Sci [Suppl 4] 25: S368–S370
Zhang ET, Inman CB, Weller RO (1990) Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. J Anat 170: 111–123
Zivkovic SA, Heyman R, Pless M (2003) Subacute rhombencephalitis optica responsive to intravenous immunoglobulins. Eur J Neurol 10: 83–86
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Anhang
Anhang
Rights and permissions
About this article
Cite this article
Jarius, S., Wildemann, B. Neuromyelitis optica. Nervenarzt 78, 1365–1377 (2007). https://doi.org/10.1007/s00115-007-2262-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-007-2262-8